Theodore Bash
Family Medicine · West Branch, MINPI 1215987235
Payments from drug & device makers
Across 439 payments — averaging $42.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$12K
- Lilly USA, LLC$1000
- Novo Nordisk$921
- AstraZeneca$731
- Boehringer Ingelheim$469
- Novartis$456
- plus $3K from 31 others
What the payments were for
- Food & beverage$6,96137%
- Education$1051%
- Gifts$11,66562%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 34 | $12,170 |
| Lilly USA, LLC | 73 | $1,000 |
| Novo Nordisk | 60 | $921 |
| AstraZeneca | 37 | $731 |
| Boehringer Ingelheim | 17 | $469 |
| Novartis | 29 | $456 |
| Pfizer | 23 | $357 |
| Bayer | 19 | $342 |
| Johnson & Johnson | 16 | $271 |
| Amgen | 14 | $244 |
| Sunovion Pharmaceuticals Inc. | 25 | $243 |
| Otsuka America Pharmaceutical, Inc. | 8 | $217 |
| Mylan Specialty L.p. | 13 | $185 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $154 |
| GSK | 8 | $129 |
| Merck | 8 | $114 |
| E.r. Squibb & Sons, L.L.C. | 6 | $93 |
| Sanofi-aventis U.S. LLC | 5 | $71 |
| Axsome Therapeutics, Inc. | 4 | $71 |
| Amarin Pharma, Inc. | 3 | $57 |
| Astellas Pharma US Inc | 2 | $46 |
| Dexcom, Inc. | 3 | $46 |
| Teva Pharmaceuticals USA, Inc. | 3 | $40 |
| Xeris Pharmaceuticals, Inc. | 2 | $40 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $38 |
| Lundbeck LLC | 2 | $35 |
| Radius Health, Inc. | 2 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| Nestle Healthcare Nutrition Inc. | 1 | $20 |
| Eisai Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Medtronic | 1 | $15 |
| Aimmune Therapeutics, Inc. | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Abbott | 1 | $12 |
| Neurocrine Biosciences, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX COSMETIC$11,665
- Ozempic$125
- ABILIFY MAINTENA$125
How this compares
$18,732 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EnbrelEtanercept | 30 | $201,488 |
| EliquisApixaban | 166 | $169,384 |
| JardianceEmpagliflozin | 121 | $104,790 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 98 | $102,738 |
| XareltoRivaroxaban | 57 | $47,476 |
| TradjentaLinagliptin | 45 | $42,135 |
| JanuviaSitagliptin Phosphate | 27 | $40,182 |
| MounjaroTirzepatide | 37 | $39,404 |
| TrulicityDulaglutide | 31 | $36,951 |
| FarxigaDapagliflozin Propanediol | 26 | $32,986 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $29,346 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 54 | $28,679 |
| LinzessLinaclotide | 37 | $27,889 |
| ZenpepLipase/Protease/Amylase | 18 | $26,905 |
| MyrbetriqMirabegron | 36 | $26,802 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel | $244 | $201,48830 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Stiolto Respimat | $469 | $172,047195 claims |
| PfizerEliquis | $357 | $169,384166 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $129 | $111,239114 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,000 | $76,35568 claims |
| Johnson & JohnsonXarelto | $271 | $47,47657 claims |
| MerckJanuvia | $114 | $40,18227 claims |
| AstraZenecaFarxiga, Symbicort | $731 | $38,04442 claims |
| AbbVieLinzess, Restasis Multidose | $12,170 | $35,33249 claims |
| Aimmune Therapeutics, Inc.Zenpep | $15 | $26,90518 claims |
| Astellas Pharma US IncMyrbetriq | $46 | $26,80236 claims |
| NovartisEntresto | $456 | $22,69114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in West Branch
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.